Assessment of the efficacy and medication adherence of fluticasone propionate–salmeterol combination delivered via a capsule-based dry powder inhaler in asthmatic patients
Main Article Content
Keywords
Asthma, Fluticasone propionate-salmeterol combination, Capsule-based dry powder inhaler, Asthma control test, Morisky Medication Adherence Scale-8, Pulmonary function tests
Abstract
Introduction: The primary treatment for asthma is inhaled medication, and therefore, regular patient follow-up significantly impacts treatment outcomes. This study aimed to retrospectively evaluate the efficacy of fluticasone–salmeterol combination treatment via a capsule-based dry powder inhaler and medication adherence at first and third months of treatment in asthmatic patients.
Methods: This study is an observational study retrospectively examining the clinical data of asthma patients treated with RESPIRO-D capsule inhaler. The study population consisted of adult asthma patients requiring level 3 asthma treatment according to GINA criteria. Data, including baseline and follow-up clinical characteristics such as age, gender, smoking history, body mass index, comorbidities, pulmonary function test (PFT) values, asthma control test (ACT) scores, and Morisky Medication Adherence Scale-8 (MMAS-8) scores, were obtained by reviewing patient records. PFT, ACT scores, and MMAS-8 measurements were recorded and compared at three different time points (baseline, first month, third month) in asthmatic individuals treated with a fluticasone–salmeterol capsule inhaler.
Results: In all, 131 subjects were included in the study. Statistically significant increase was seen in all lung functions in spirometric measurements recorded at baseline and at first and third months of treatment. ACT scores of subjects were increased at first month of treatment compared to baseline and further increased at third month of treatment compared to 1st month of treatment. MMAS-8 did not change significantly at first and third months of treatment. None of the patients stopped treatment due to drug-related side effects.
Conclusion: This study demonstrates that fluticasone-salmeterol capsule inhaler therapy can significantly improve symptom control and respiratory function in adult asthma patients.
References
2. Groß R, Berkenfeld K, Schulte C, Ebert A, Sule S, Sule A, et al. State of the art in capsule-based dry powder ınhalers: deagglomeration techniques and the consequences for formulation aerosolization. Pharmaceutics. 2022;14(6):1185. https://doi.org/10.3390/pharmaceutics14061185
3. Aksu K, Vural Solak GT, Mutlu LC, Mutlu P, Vayısoğlu Şahin G, Erdem Türe E, et al. Demographic and asthma-related characteristics of asthmatics using pressurized metered dose ınhalers and dry powder ınhalers. J Aerosol Med Pulm Drug Deliv. 2024;37(6):346-50. https://doi.org/10.1089/jamp.2024.0006
4. Halpin DMG, Mahler DA. Systematic review of the effects of patient errors using inhaled delivery systems on clinical outcomes in COPD. BMJ Open Respir Res. 2024;11(1):e002211. https://doi.org/10.1136/bmjresp-2023-002211
5. Marko M, Pawliczak R. Inhalation technique-related errors after education among asthma and COPD patients using different types of inhalers - systematic review and meta-analysis. NPJ Prim Care Respir Med. 2025;35(1):15. https://doi.org/10.1038/s41533-025-00422-0
6. Mairhofer J, Sangermano K, Morandell G, Piccoliori G, Engl A, Wiedermann CJ. Comparing the CO2 emissions of metered dose inhalers and dry powder inhalers: a cross-sectional environmental impact analysis of asthma and COPD therapies in South Tyrol, Italy. BMJ Open Respir Res. 2025;12(1):e002977. https://doi.org/10.1136/bmjresp-2024-002977
7. Usmani OS, Lavorini F, Marshall J, Dunlop WCN, Heron L, Farrington E, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19:10. https://doi.org/10.1186/s12931-017-0710-y
8. Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45(2):396-407. https://doi.org/10.1183/09031936.00075614
9. Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009;124(4):719-723.e1. https://doi.org/10.1016/j.jaci.2009.06.053.
10. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324-43. https://doi.org/10.1183/09031936.00080312
11. Roche N, Aggarwal B, Boucot I, Mittal L, Martin A, Chrystyn H. The impact of inhaler technique on clinical outcomes in adolescents and adults with asthma: A systematic review. Respir Med. 2022;202:106949. https://doi.org/10.1016/j.rmed.2022.106949
12. Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines: a meta-analytic review of the Necessity–Concerns Framework. PLoS One. 2013;8(12):e80633. https://doi.org/10.1371/journal.pone.0080633
13. Williams LK, Peterson EL, Wells K, Ahmedani BK, Kumar R, Burchard EG, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011;128(6):1185-1191.e2. https://doi.org/10.1016/j.jaci.2011.09.011
14. Chan A, De Simoni A, Wileman V, Holliday L, Newby CJ, Chisari C, et al. Digital interventions to improve adherence to maintenance medication in asthma. Cochrane Database Syst Rev. 2022;6(6):CD013030. https://doi.org/10.1002/14651858.CD013030.pub2
15. Almutairi M, Marriott JF, Mansur A. Effect of monitoring adherence to regular inhaled corticosteroid (ICS) alone or in combination with a long-acting β2-agonist (LABA) using electronic methods on asthma outcomes: a narrative systematic review. BMJ Open. 2023;13(8):e074127. https://doi.org/10.1136/bmjopen-2023-074127
16. Park HS, Lee J, Kim H, Woo SD. Comparative analysis of real-world data on the efficacy and safety of and adherence to ICS/LABA combinations in asthma management. Respir Res. 2025;26(1):12. https://doi.org/10.1186/s12931-024-03084-7
17. Price DB, Román-Rodríguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract. 2017;5(4):1071-1081.e9. https://doi.org/10.1016/j.jaip.2017.01.004
18. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836-44. https://doi.org/10.1164/rccm.200401-033OC
19. Baumgarten C, Geldszus R, Behre U, Peslis N, Trautmann M. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023). Eur J Med Res. 2002;7(1):1-7.
20. Murray J, Rosenthal R, Somerville L, Blake K, House K, Baitinger L, et al. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. Ann Allergy Asthma Immunol. 2004;93(4):351-9. https://doi.org/10.1016/S1081-1206(10)61394-4
21. Clark CE. Use of salmeterol/fluticasone combination (Seretide) in an asthma clinic: a pragmatic open study from primary care. Prim Care Respir J. 2003;12(3):86-89. https://doi.org/10.1038/pcrj.2003.53